about
Application of cross-species PET imaging to assess neurotransmitter release in brainLarvae of the small white butterfly, Pieris rapae, express a novel serotonin receptorDopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptorsRetinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-AntagonistPsychedelicsFos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaineComparative assessment of (18) F-Mefway as a serotonin 5-HT1A receptor PET imaging agent across species: Rodents, nonhuman primates, and humansFunctional interactions between 5-HT2A and presynaptic 5-HT1A receptor-based responses in mice genetically deficient in the serotonin 5-HT transporter (SERT)Treatment with the antipsychotic agent, risperidone, reduces disease severity in experimental autoimmune encephalomyelitis.Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors.5-HT radioligands for human brain imaging with PET and SPECTAutoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain.Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders.Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.PET tracers for serotonin receptors and their applicationsLigand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonistsPsilocybin-induced stimulus control in the rat.Molecular Targets of Cannabidiol in Neurological DisordersDisruption of 5-HT1A function in adolescence but not early adulthood leads to sustained increases of anxietyModification of the behavioral effects of morphine in rats by serotonin 5-HT₁A and 5-HT₂A receptor agonists: antinociception, drug discrimination, and locomotor activity.Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents.Opposing actions of 5HT1A and 5HT2-like serotonin receptors on modulations of the electric signal waveform in the electric fish Brachyhypopomus pinnicaudatus.Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on L-dopa dependent animal involuntary movements in rats.Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in ratsSynthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.Current status of positron emission tomography radiotracers for serotonin receptors in humans.Non human primate models for Alzheimer's disease-related research and drug discovery.Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.Three amino acids in the D2 dopamine receptor regulate selective ligand function and affinity.Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions.Serotonin 1A receptor inhibits the status epilepticus induced by lithium-pilocarpine in rats.Serotonin modulates the excitatory synaptic transmission in the dentate granule cells.Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats.MDMA modulates spontaneous firing of subthalamic nucleus neurons in vitro.Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists.Neuronal control of pedal sole cilia in the pond snail Lymnaea stagnalis appressa.Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775).Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus.Electroacupuncture alleviates chemotherapy-induced pain through inhibiting phosphorylation of spinal CaMKII in rats.
P2860
Q26865012-690B160D-D118-473A-95A2-A153908E3E54Q28247281-1C0E4789-4D41-4B9A-9B5D-E7EF1B006708Q28273285-299082FF-1C27-44BB-B866-8CA88CF434BEQ28552843-9A62DF54-6411-4EAB-BC58-D1174C64B400Q30359998-3F5E2D12-9856-4A97-A35B-98A3A250A0B7Q30424415-F88934D4-7220-4ACF-88A7-7679EA36BCE1Q30724808-95A3DEE5-5E5A-4B6D-9B1F-255951A69CCFQ33690754-46EF963C-D9C0-4DD7-8D63-E3C611FA599DQ34035137-11CE01F1-483E-4386-AB63-AA10C3A332B7Q34087847-A33BAADC-BFFB-43F3-95C1-E6B92B0D197AQ34192729-CBD02A44-14C3-498A-B256-392469C59A68Q34214169-1AEBA5B2-1BDD-45C6-A4C6-61E667DB1960Q34425116-238C299B-D9C2-44C0-A71E-6DB700CC000DQ35025821-AFF1FC58-1F83-44A0-ADB5-B9764B7117C2Q35090637-D103CD69-9538-4096-809C-1D8FCDC54737Q35913125-8A332B31-5A54-47F1-9C0C-14C30A36801CQ36023615-95B8CBDB-72FB-42AE-9172-6488B361CDC2Q36157649-B34EA5F7-28D5-4782-89DA-858CE03794AEQ36345622-46EDC039-ECBA-4A54-960C-5819BBA590C5Q36545184-C3BA7BF5-F2EF-488A-9A90-14257651A5FDQ36569714-702A61ED-BCDC-4A03-A11C-C70D93CD9827Q36923709-75CCD9E3-410B-416B-92DA-3F737D605BCAQ37286549-3C41028A-CFC7-4EF8-9583-F015F2104105Q37286573-A9F67155-CFE3-42A7-BA43-D98CC4AB6AC0Q37380723-A2475D61-0DFC-4D00-9198-D9D449760863Q38166965-965487BF-CD73-42F1-A91A-85B11B593A96Q38783343-A674DD6C-0E65-4894-BB02-358F4D53C8F2Q39166556-FE0D918E-2968-46B2-9FD2-FFA58CAAC283Q39844414-546E2CF5-5E42-42F8-9DE4-09EB39F0592BQ40226041-8DAB2B57-3654-4D0F-92A7-82B71F9263B4Q41458065-6E086419-EE19-4B5C-83C2-16F429533AABQ41817982-6B6F64EE-CB02-4FA2-813F-642C9C052F4CQ42055790-595091E9-3FDF-4EA9-A854-5220CCEBB031Q42465875-F9759591-EC3E-4515-BF80-A6A60337A804Q42700473-EF37CC02-D2E2-4941-9AC9-5A22CA23223CQ44968836-21CD24E6-C877-41A9-9997-A1038AFCC3F7Q45797696-6665113E-27BA-4933-878C-A9DA03DFA30AQ46573497-2EF71A2A-9C91-4E25-90F5-D2A12B50EAADQ46640346-5AE1A190-E2A0-44D9-AA76-DFD4B4FE91CCQ47649743-CA01F73F-5AF9-439E-9F02-9C2AC9ACFDAC
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
WAY-100635 is a potent dopamine D4 receptor agonist
@ast
WAY-100635 is a potent dopamine D4 receptor agonist
@en
WAY-100635 is a potent dopamine D4 receptor agonist
@nl
type
label
WAY-100635 is a potent dopamine D4 receptor agonist
@ast
WAY-100635 is a potent dopamine D4 receptor agonist
@en
WAY-100635 is a potent dopamine D4 receptor agonist
@nl
prefLabel
WAY-100635 is a potent dopamine D4 receptor agonist
@ast
WAY-100635 is a potent dopamine D4 receptor agonist
@en
WAY-100635 is a potent dopamine D4 receptor agonist
@nl
P2093
P3181
P1433
P1476
WAY-100635 is a potent dopamine D4 receptor agonist
@en
P2093
Benjamin R Chemel
Blaine Armbruster
Bryan L Roth
David E Nichols
Val J Watts
P2888
P304
P3181
P356
10.1007/S00213-006-0490-4
P407
P577
2006-10-01T00:00:00Z
P6179
1046544890